DENTSPLY SIRONA Inc. $XRAY Shares Bought by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC grew its position in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 812.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 176,832 shares of the medical instruments supplier’s stock after purchasing an additional 157,448 shares during the period. Kingsview Wealth Management LLC owned approximately 0.09% of DENTSPLY SIRONA worth $2,244,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Parkside Financial Bank & Trust boosted its position in DENTSPLY SIRONA by 620.6% in the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 1,477 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in DENTSPLY SIRONA during the 1st quarter valued at approximately $26,000. True Wealth Design LLC boosted its holdings in shares of DENTSPLY SIRONA by 273.0% in the 2nd quarter. True Wealth Design LLC now owns 2,376 shares of the medical instruments supplier’s stock valued at $38,000 after acquiring an additional 1,739 shares during the last quarter. Huntington National Bank increased its stake in shares of DENTSPLY SIRONA by 292.9% in the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 2,077 shares during the period. Finally, Central Pacific Bank Trust Division lifted its position in DENTSPLY SIRONA by 100.0% during the third quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 2,000 shares during the period. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Trading Up 1.1%

Shares of XRAY stock opened at $13.44 on Thursday. DENTSPLY SIRONA Inc. has a 1-year low of $9.85 and a 1-year high of $17.18. The company has a market cap of $2.68 billion, a price-to-earnings ratio of -4.48, a PEG ratio of 1.56 and a beta of 0.97. The company has a debt-to-equity ratio of 1.50, a current ratio of 1.51 and a quick ratio of 1.03. The stock has a 50 day simple moving average of $12.56 and a 200-day simple moving average of $12.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). The company had revenue of $961.00 million during the quarter, compared to analysts’ expectations of $926.40 million. DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.DENTSPLY SIRONA’s revenue was up 6.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.26 EPS. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities research analysts expect that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, January 9th. Investors of record on Friday, December 26th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 4.8%. The ex-dividend date was Friday, December 26th. DENTSPLY SIRONA’s dividend payout ratio is -21.33%.

DENTSPLY SIRONA News Summary

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Director purchases: Long‑time director Gregory T. Lucier bought sizable blocks of stock on March 2 and March 3 (27,555 shares at ~$14.24 and 22,445 shares at ~$14.03), raising his ownership to ~50,000 shares — a strong insider confidence signal. InsiderTrades Article
• Positive Sentiment: Barrington Research raised its price target to $17 — an upbeat analyst action that implies meaningful upside relative to current levels and can attract buyer interest. Barrington Research PT Raise
• Positive Sentiment: Zacks upgraded XRAY from “strong sell” to “hold,” removing a negative rating and potentially supporting short‑term sentiment improvement. Zacks Upgrade
• Neutral Sentiment: Mizuho raised its price target to $16 but left a “neutral” rating — modestly positive for price targets but limited catalyst without a rating upgrade. Mizuho Note
• Neutral Sentiment: Investor access: Management will present at the Leerink Partners Global Healthcare Conference (Mar 10) — a scheduled event that could provide fresh guidance or color but is not itself a guaranteed catalyst. Conference Notice
• Neutral Sentiment: Fundamental watch‑items: Coverage notes flag international revenue trends and mixed analyst targets (average PT ~$14.42) — useful context for modeling but neither clearly bullish nor bearish on its own. Zacks Analysis
• Neutral Sentiment: Short‑interest reporting appears anomalous (reports showing zero/NaN), so treat any short‑squeeze narratives as unreliable until corrected data is posted.
• Negative Sentiment: Earnings & guidance caveat: The company slightly missed quarterly EPS consensus (by ~$0.01) despite a revenue beat, and FY‑2026 guidance (1.40–1.50 EPS) sits below some sell‑side estimates (~1.84), which could cap upside if analysts lower forecasts. MarketBeat Summary

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on XRAY shares. Bank of America raised DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price target for the stock from $13.00 to $17.00 in a research report on Thursday, February 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Barclays began coverage on DENTSPLY SIRONA in a research report on Monday, December 8th. They set an “underweight” rating and a $12.00 price target for the company. Robert W. Baird upped their price objective on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 27th. Finally, Barrington Research lifted their target price on shares of DENTSPLY SIRONA from $14.00 to $17.00 and gave the company an “outperform” rating in a report on Monday. Three analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, DENTSPLY SIRONA has an average rating of “Hold” and an average target price of $14.42.

Insiders Place Their Bets

In related news, Director Gregory T. Lucier sold 82,200 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $11.14, for a total value of $915,708.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 0.50% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.